Welcome to our dedicated page for BIO-TECHNE SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
Bio-Techne Corporation reported fourth-quarter fiscal 2026 net sales of $321.2 million, up 1% year over year, with organic revenue up 3%. GAAP diluted EPS improved to $0.35 from a loss of $(0.11), while adjusted EPS was $0.52 versus $0.53. GAAP operating income was $74.3 million compared with a prior-year loss, and GAAP operating margin rose to 23.1%, helped by the absence of last year’s impairment. Adjusted operating income increased to $103.4 million and adjusted operating margin to 32.2%.
For full-year fiscal 2026, net sales were flat at $1.22 billion. GAAP diluted EPS increased to $1.16 from $0.46, and adjusted EPS edged up to $1.93 from $1.92. Full-year GAAP operating income rose to $251.9 million with a 20.7% operating margin, while adjusted operating income reached $386.1 million. The Protein Sciences segment grew revenue 1% to $874.6 million with a 41.1% operating margin; Diagnostics and Spatial Biology revenue declined 3% to $336.4 million, but its operating margin improved to 11.2%.
The company highlighted a previously announced agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, implying enterprise value of about $11.3 billion. Bio-Techne also declared a quarterly cash dividend of $0.08 per share, payable September 4, 2026, to shareholders of record on August 24, 2026.
Bio-Techne Corporation has agreed to be acquired by Merck KGaA, Darmstadt, Germany through a cash merger. Under an Agreement and Plan of Merger signed on June 25, 2026, each outstanding share of Bio-Techne common stock (other than specified excluded and dissenting shares) will be converted at the effective time into the right to receive $73.00 in cash per share, without interest and subject to tax withholding. After completion, Bio-Techne will become a wholly owned subsidiary of Merck KGaA and its shares will cease to trade on Nasdaq.
The merger must be approved by holders of a majority of the voting power of outstanding shares entitled to vote at a special virtual shareholder meeting. The board of directors unanimously determined the merger to be advisable and in the best interests of shareholders and recommends voting FOR the merger and related proposals. Goldman Sachs & Co. LLC provided a fairness opinion that the $73.00 cash consideration is fair from a financial point of view and is to receive a contingent transaction fee of about $106 million if the deal closes.
If the merger is not completed, Bio-Techne will remain public and its stock will continue trading on Nasdaq; the company notes the share price could decline and may not return to pre-announcement levels. Under specified termination scenarios, Bio-Techne may owe Merck KGaA a $230,455,000 termination fee, and in other scenarios Merck KGaA may owe Bio-Techne a $576,140,000 reverse termination fee. The transaction is not conditioned on financing, and required antitrust and investment-screening approvals, including under the HSR Act, must be obtained.
FMR LLC and Abigail P. Johnson report beneficial ownership of BIO-TECHNE CORP common stock on an amended Schedule 13G. As of June 30, 2026, FMR LLC reports beneficial ownership of 12,754,783.64 shares, representing 8.1% of the class. FMR LLC has sole voting power over 12,715,889.05 shares and sole dispositive power over 12,754,783.64 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 12,754,783.64 shares, with no voting power. The filing notes that the shares are held on behalf of one or more other persons entitled to dividends or sale proceeds, but no such person holds more than five percent of BIO-TECHNE CORP’s outstanding common stock.
Bio-Techne Corp CFO James Hippel exercised stock options covering 62,068 shares of common stock on July 29, 2026 at an exercise price of $47.60 per share. A separate Form 4 entry shows 51,024 shares of common stock disposed of at $72.03 per share, designated as payment of exercise price or tax liability by withholding securities. He continues to hold multiple option and restricted stock unit awards, including options over 167,328 shares at an exercise price of $66.97 expiring August 5, 2027.
Bio-Techne Corp CEO Kim Kelderman exercised stock options for 35,000 shares of common stock at an exercise price of $47.60 per share on 2026-07-28. He acquired these shares directly and had 28,686 shares of common stock withheld at $72.07 per share to pay the option exercise price or related tax liabilities. He continues to hold multiple stock option and restricted stock unit awards with various exercise prices, vesting dates and expirations.
Bio-Techne Corp SVP and General Counsel Shane Bohnen exercised stock options for 448 shares of common stock on 2026-07-23 at an exercise price of 47.6000 per share, converting an option on 448 shares into directly held stock. To satisfy the exercise price or related tax obligations, 344 shares of common stock were withheld at 71.7700 per share. He continues to hold multiple option and stock-unit awards, including stock options over 8,944 shares at a 66.9700 exercise price expiring 2027-08-05 and 3,460 shares at 120.4600 expiring 2028-08-06. The filing indicates these transactions were not made under a Rule 10b5-1 trading plan.
Bio-Techne Corporation has agreed to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash merger. Each outstanding share of Bio-Techne common stock (other than excluded and restricted shares) will be converted into the right to receive $73.00 in cash, subject to tax withholding.
Vested stock options will be cashed out for the in-the-money value, while unvested options, RSUs, PSUs and restricted stock convert into cash-based awards that retain their vesting schedules. Closing requires shareholder approval and antitrust and investment screening clearances, with an outside date of March 25, 2027, extendable to September 25, 2027. The company may owe Merck a $230.455 million termination fee in certain scenarios, while Merck may owe Bio-Techne $576.14 million in others. Named executives receive substantial cash retention bonuses payable at closing or if the merger agreement terminates under specified conditions.
Bio-Techne Corporation agreed to be acquired by Merck KGaA, Darmstadt, Germany for US$73 per share in cash, implying a total enterprise value of about US$11.3 billion and a 36% premium to Bio-Techne’s one-month volume weighted average price.
The deal, unanimously approved by Bio-Techne’s board and Merck’s relevant corporate bodies, is expected to close by late 2026 or early 2027, subject to shareholder and regulatory approvals and other customary conditions. Merck plans to fund the purchase with existing cash and new debt while maintaining an investment-grade rating.
Management expects the transaction to be immediately accretive to EBITDA pre margin for Merck’s Life Science business and to become EPS pre accretive by year three after closing, supported by about EUR 140 million of cost synergies targeted by year three. Bio-Techne generated net sales of more than US$1.2 billion in fiscal year 2025 and brings strong positions in multi-omics, spatial biology, cell and gene therapy, and precision diagnostics.
BIO-TECHNE Corp executive Steven C. Crouse reported routine equity compensation activity and updated holdings. On June 2, 2026, he exercised 600 restricted stock units into an equal number of common shares and had 216 shares of common stock withheld at $49.77 per share to satisfy tax obligations. Following the tax withholding, he directly held 6,761 shares of common stock. The filing also lists multiple outstanding stock options and restricted stock unit awards with exercise prices between $48.61 and $120.46 per share and expirations through 2036, indicating a substantial remaining equity position. A footnote states that a mathematical error in a prior Form 4 increased the reported beneficial ownership by 40 shares, and this filing reflects the corrected total.
BIO-TECHNE Corp director Amy E. Herr reported an exercise-and-sale transaction carried out through an account held by her significant other. On May 8, 2026, that account exercised 6,636 shares of BIO-TECHNE common stock at an exercise price of $47.60 per share and received the underlying shares.
On the same date, the same account sold 6,636 shares of common stock at a weighted average price of about $48.28 per share, leaving 200 indirect shares of common stock held by the significant other. Separately, Herr holds 2,680 shares of common stock directly, along with a range of stock options and restricted stock units that continue to represent additional exposure to BIO-TECHNE stock.